The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
Open accessAbstract
We evaluated the safety and efficacy of high-dose, posttransplantation cyclophosphamide (Cy) to prevent graft rejection and graft-versus-host disease (GVHD) after outpatient nonmyeloablative conditioning and T cell-replete bone marrow transplantation from partially HLA-mismatched (haploidentical) related donors. Patients with advanced hematologic malignancies (n = 67) or paroxysmal nocturnal hemoglobinuria (n = 1) received Cy 50 mg/kg i.v. on day 3 (n = 28) or on days 3 and 4 (n = 40) after transplantation. The median times to neutrophil (>500/microL) and platelet recovery (>20,000/microL) were 15 and 24 days, respectively. Graft failure occurred in 9 of 66 (13%) evaluable patients, and was fatal in 1. The cumulative incidences of grades II-IV and grades III-IV acute (aGVHD) by day 200 were 34% and 6%, respectively. There was a trend toward a lower risk of extensive chronic GVHD (cGVHD) among recipients of 2 versus 1 dose of posttransplantation Cy (P = .05), the only difference between these groups. The cumulative incidences of nonrelapse mortality (NRM) and relapse at 1 year were 15% and 51%, respectively. Actuarial overall survival (OS) and event-free survival (EFS) at 2 years after transplantation were 36% and 26%, respectively. Patients with lymphoid malignancies had an improved EFS compared to those with myelogenous malignancies (P = .02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
Clues to the Pathogenesis of Familial Colorectal Cancer
Aaltonen, L. A., Peltomäki, P., Leach, F. S., Sistonen, P., Pylkkänen, L., Mecklin, J.-P., Järvinen, H., Powell, S. M., Jen, J., Hamilton, S. R., et al. (1993) · Science · doi:10.1126/science.8484121 · Cited by 2,710
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Self-citationByrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,597
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Aversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Laughlin, M. J., Eapen, M., Rubinstein, P., Wagner, J. E., Zhang, M.-J., Champlin, R. E., Stevens, C., Barker, J. N., Gale, R. P., Lazarus, H. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041276 · Cited by 1,062
Cited by
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Cyclophosphamide and cancer: golden anniversary
Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,050
Self-citationPost-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
Bolaños-Meade, J., Hamadani, M., Wu, J., Al Malki, M. M., Martens, M. J., Runaas, L., Elmariah, H., Rezvani, A. R., Gooptu, M., Larkin, K. T., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215943 · Cited by 603
Self-citationPhase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Kebriaei, P., Singh, H., Huls, M. H., Figliola, M. J., Bassett, R., Olivares, S., Jena, B., Dawson, M. J., Kumaresan, P. R., Su, S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86721 · Cited by 500
Bashey, A., Zhang, X., Sizemore, C. A., Manion, K., Brown, S., Holland, H. K., Morris, L. E., & Solomon, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3523 · Cited by 499
Modern Therapy of Acute Lymphoblastic Leukemia
Bassan, R., & Hoelzer, D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1382 · Cited by 485
Leventhal, J., Abecassis, M., Miller, J., Gallon, L., Ravindra, K., Tollerud, D. J., King, B., Elliott, M. J., Herzig, G., Herzig, R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003509 · Cited by 463
Bolaños-Meade, J., Fuchs, E. J., Luznik, L., Lanzkron, S. M., Gamper, C. J., Jones, R. J., & Brodsky, R. A. (2012) · Blood · doi:10.1182/blood-2012-07-438408 · Cited by 444
Self-citationHigh-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease
Luznik, L., Bolaños-Meade, J., Zahurak, M., Chen, A. R., Smith, B. D., Brodsky, R., Huff, C. A., Borrello, I., Matsui, W., Powell, J. D., et al. (2010) · Blood · doi:10.1182/blood-2009-11-251595 · Cited by 409
Self-citationHematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Bader, P., Bonini, C., Cesaro, S., Dreger, P., Duarte, R. F., Dufour, C., Kuball, J., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.20 · Cited by 402
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Bader, P., Bonini, C., Duarte, R. F., Dufour, C., Gennery, A., Kröger, N., Kuball, J., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.34 · Cited by 395
Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.52 · Cited by 387
Kanakry, C. G., Ganguly, S., Zahurak, M., Bolaños-Meade, J., Thoburn, C., Perkins, B., Fuchs, E. J., Jones, R. J., Hess, A. D., & Luznik, L. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006960 · Cited by 357
Self-citationHematopoietic stem cell transplantation for patients with AML in first complete remission
Cornelissen, J. J., & Blaise, D. (2016) · Blood · doi:10.1182/blood-2015-07-604546 · Cited by 346
Sureda, A., Bader, P., Cesaro, S., Dreger, P., Duarte, R. F., Dufour, C., Falkenburg, J. H. F., Farge-Bancel, D., Gennery, A., Kröger, N., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.6 · Cited by 337
Luznik, L., O'Donnell, P. V., & Fuchs, E. J. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.09.005 · Cited by 336
Self-citationModern approaches to HLA-haploidentical blood or marrow transplantation
Kanakry, C. G., Fuchs, E. J., & Luznik, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.128 · Cited by 330
Self-citationClassification systems for chronic graft-versus-host disease
Lee, S. J. (2017) · Blood · doi:10.1182/blood-2016-07-686642 · Cited by 307
McCurdy, S. R., Kanakry, J. A., Showel, M. M., Tsai, H.-L., Bolaños-Meade, J., Rosner, G. L., Kanakry, C. G., Perica, K., Symons, H. J., Brodsky, R. A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-623991 · Cited by 303
Self-citationBolaños-Meade, J., Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30221-7 · Cited by 287
Self-citationRaiola, A. M., Dominietto, A., di Grazia, C., Lamparelli, T., Gualandi, F., Ibatici, A., Bregante, S., Van Lint, M. T., Varaldo, R., Ghiso, A., et al. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.05.029 · Cited by 283
Kasamon, Y. L., Luznik, L., Leffell, M. S., Kowalski, J., Tsai, H.-L., Bolaños-Meade, J., Morris, L. E., Crilley, P. A., O'Donnell, P. V., Rossiter, N., et al. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.11.011 · Cited by 281
Self-citationKanakry, C. G., O'Donnell, P. V., Furlong, T., de Lima, M. J., Wei, W., Medeot, M., Mielcarek, M., Champlin, R. E., Jones, R. J., Thall, P. F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0625 · Cited by 278
Self-citationKröger, N. M., Deeg, J. H., Olavarria, E., Niederwieser, D., Bacigalupo, A., Barbui, T., Rambaldi, A., Mesa, R., Tefferi, A., Griesshammer, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.233 · Cited by 277
Acute graft-versus-host disease
Malard, F., Holler, E., Sandmaier, B. M., Huang, H., & Mohty, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00438-1 · Cited by 268
Self-citationBurroughs, L. M., O'Donnell, P. V., Sandmaier, B. M., Storer, B. E., Luznik, L., Symons, H. J., Jones, R. J., Ambinder, R. F., Maris, M. B., Blume, K. G., et al. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.08.014 · Cited by 266
Self-citationCiurea, S. O., Cao, K., Fernandez-Vina, M., Kongtim, P., Malki, M. A., Fuchs, E., Luznik, L., Huang, X.-J., Ciceri, F., Locatelli, F., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-017-0062-8 · Cited by 257
Self-citationPathophysiology of GvHD and Other HSCT-Related Major Complications
Ghimire, S., Weber, D., Mavin, E., Wang, X. N., Dickinson, A. M., & Holler, E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00079 · Cited by 256
Fabricius, W. A., & Ramanathan, M. (2016) · Advances in Hematology · doi:10.1155/2016/5726132 · Cited by 46
Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?
Leonard, A., Tisdale, J., & Abraham, A. (2020) · British Journal of Haematology · doi:10.1111/bjh.16437 · Cited by 45
Ortí, G., Gras, L., Koster, L., Kulagin, A., Byrne, J., Apperley, J. F., Halaburda, K., Blau, I. W., Clark, A., Kröger, N., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.09.019 · Cited by 9
Van Beek, J. J. P., Puccio, S., Roberto, A., De Paoli, F., Graziano, G., Salviato, E., Alvisi, G., Zanon, V., Scarpa, A., Zaghi, E., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.276352 · Cited by 6
Metadata
- Authors
- Luznik, L., O'Donnell, P. V., Symons, H. J., Chen, A. R., Leffell, M. S., Zahurak, M., Gooley, T. A., Piantadosi, S., Kaup, M., Ambinder, R. F., Huff, C. A., Matsui, W., Bolaños-Meade, J., Borrello, I., Powell, J. D., Harrington, E., Warnock, S., Flowers, M., Brodsky, R. A., Sandmaier, B. M., Storb, R. F., Jones, R. J., & Fuchs, E. J.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2008-06
- Volume
- 14
- Issue
- 6
- Pages
- 641-650
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2039334806
- Cited by
- 1,938
- References
- 39
- FWCI
- 16.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.